CLN1 Disease Clinical Trial Achieves Critical Milestone in Canada

By Laura King Edwards

This week, Taysha Gene Therapies (Taysha) announced an important milestone for TSHA-118, its CLN1 disease (Batten disease) clinical trial.

The news signifies one more giant step toward achieving the dream driven by Taylor’s 2006 diagnosis. They say it takes a village, and that couldn’t be closer to the truth. We’re grateful to the entire team at Taysha as well as our friend, the incomparable Steven Gray, PhD, who developed the treatment in his lab with support from Taylor’s Tale. If not for Dr. Gray’s passion, persistence and prowess, families fighting CLN1 disease would have far less hope today.

Please read the community letter below. The clinical trial is not enrolling patients at this time, but if you have questions, please contact Taysha.

Leave a Reply

Your email address will not be published. Required fields are marked *